Market Intelligence, Clinical Progress, and High-Purity Reagents for SAM Metabolism & Synthetic Lethality Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAT2A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | MAT2A Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View MAT2A Products |
| Antigen (Mutant) | MAT2A Drug-Resistant Mutant Panel Resistance variants for mechanism studies. E. coli/HEK293 expressed. |
View MAT2A Products |
| Gene Delivery | MAT2A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. CMV promoter. |
View MAT2A Products |
| Benchmark Ab | Anti-MAT2A (Clone MAT2A-001) Recombinant rabbit mAb for Western/ELISA validation. |
View MAT2A Products |
| Validator | MAT2A siRNA Set For knockdown verification and specificity controls. |
View MAT2A Products |
| Synthetic Lethal Partner | MTAP (Methylthioadenosine Phosphorylase) Pathway complement for synthetic lethality assays. |
View MTAP Products |
| Downstream Target | PRMT5 (Protein Arginine Methyltransferase 5) SAM-dependent methyltransferase; functional assay pairing. |
View PRMT5 Products |
| Isoform Control | MAT1A (Methionine Adenosyltransferase 1A) Liver-specific isoform for selectivity screening. |
View MAT1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (MAT2A vs MAT1A) | Ortholog proteins strictly verified by mass spec; Human MAT2A and MAT1A available with >95% purity for parallel screening. |
| Drug Resistance Profiling | Mutant MAT2A variants (resistance alleles) sequence-verified for mechanism-of-action studies. |
| Enzymatic Activity Validation | High-purity WT protein with validated ATP/Met binding sites; suitable for IC50 determination. |
| Synthetic Lethality Confirmation | MTAP protein pairing available for biochemical rescue assays. |
| Cellular SAM Depletion Assays | Validated siRNA included for specificity checks; Lentivirus for stable overexpression. |
Live MAT2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAT2A therapeutics centers on exploiting synthetic lethality in MTAP-deleted cancers (approximately 15% of all solid tumors). As first-generation inhibitors (IDE397, originally from Agios/Servier and now developed by IDEAYA Biosciences) advance through Phase II, the competitive landscape is shifting toward combination strategies with PRMT5 inhibitors and next-generation compounds targeting CNS penetration. The next wave of R&D focuses on resistance mutation profiling and isoform-selective inhibitors to minimize hepatic toxicity. Key players include IDEAYA, Servier, and emerging biotechs focusing on PROTAC degraders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | IDEAYA Biosciences, Servier (formerly Agios) | MTAP-deleted Solid Tumors (NSCLC, Pancreatic) | Enzymatic Activity Assay (Need high-purity WT and Mutant proteins) |
| Combination Therapy | IDEAYA + GSK (PRMT5i) | MTAP-deleted Tumors | SAM Depletion Quantification (Need MAT2A/PRMT5 protein pairs) |
| PROTAC/Degrader | Preclinical (Emerging Biotechs) | Refractory Tumors | Ternary Complex Validation (Need high-purity tagged proteins) |
| Brain-Penetrant Inhibitors | Agios (Pipeline) | Brain Metastases, Gliomas | Stability Assays (Need high-concentration protein standards) |
TarMart Execution Strategy
To fully support MAT2A drug discovery, TarMart recommends focusing on the Drug Resistance Mutant Panel as a key differentiator, since resistance mechanisms are emerging alongside clinical progress. Additionally, offering high-purity WT protein for enzymatic assays, Lentivirus for isogenic cell line construction, and pairing reagents for synthetic lethality confirmation (MTAP, PRMT5, MAT1A) provides a complete workflow. All proteins are sequence-verified and quality-controlled to >95% purity.